2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1190

Use of Biologic Drugs and Adverse Events in Patients with Rheumatic Disease: DATA from the Mexican Biologics Registry
Abstract Number: 334

Use of Handheld Device to Enhance Patient Reported Outcome Measure Data Collection in an Academic Rheumatology Practice
Abstract Number: 329

Use of Inter-Professional Collaboration to Improve Adherence to American College of Rheumatology Recommendations for Use of Disease Activity Measures
Abstract Number: 344

Use of Lean Six-Sigma Methodologies to Improve Pneumococcal Vaccination Rates Among Immunocompromised Veterans with Rheumatologic Diseases: A Quality Improvement Project
Abstract Number: 2545

Use of Oral Complementary Medicine in Inflammatory Arthritis: Data from the Australian Rheumatology Association Database (ARAD)
Abstract Number: 2189

Use of Smartphones in Collecting Patient Reported Outcomes (PROs): Feasibility of a Study Nested in a US National Cohort
Abstract Number: 2371

Use of Social Media Among Patients with Rheumatic Diseases
Abstract Number: 819

Use of Takayasu Arteritis Damage Score (TADS) to Measure Damage in Takayasu Arteritis
Abstract Number: 1437

Use,Safety and Efficacy of Thalidomide from a Tertiary Level Pediatric Rheumatology Centre in India
Abstract Number: 1560

Usefulness of 18F-FDG Positron Emission Tomography for Lymphoma Diagnosis in Patients with Primary Sjögren’S Syndrome
Abstract Number: 1679

Usefulness of Cardiac Screening in Patients with Systemic Lupus Erythematosus and Anti-Ro Positive Antibodies
Abstract Number: 2213

Usefulness of Shoulder Radiographs to Aid in Determining Need for Advanced Imaging to Detect Operable or Inoperable Full-Thickness Rotator Cuff Tears
Abstract Number: 2192

User Experience with Methotrexate in Managing Inflammatory Arthritis Under the Support of an Interprofessional Arthritis Care Team (UMTX Study)
Abstract Number: 2103

Using a Drosophila Model to Unravel the Genetic Complexity of Systemic Lupus Erythematosus
Abstract Number: PP10

Using a Mobile App to Facilitate Patient-Doctor Discussions to Make Informed Decisions Regarding ‘Painsomnia’

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].